Compare Abbott Laboratories (ABT) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Credo Technology Group Holding Ltd — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Credo Technology Group Holding Ltd trades at $254.35 (market cap $45.95B). The key difference: Abbott Laboratories is far larger — about 3.6× Credo Technology Group Holding Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| ABT | CRDO | |
|---|---|---|
Market Cap | $166.94B | $45.95B |
Sector | Health | Technology |
52-Week High | $136.62 | $302.52 |
52-Week Low | $82.57 | $87.81 |
Enterprise Value | $193.69B | $44.53B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CRDO trades at $265.55, up 9.77% in 24 hours, with strong bullish momentum from moving averages and recent earnings beats. The stock shows robust fundamentals with 35.37% net income margin and 34.41% ROE, though valuations are elevated at P/E 105.8 and P/S 37.44. Recent news highlights AI-driven growth in connectivity solutions, with revenue surging 157% YoY in Q4 2026.
Outlook remains positive given analyst consensus of $273.33 price target and 86.7% buy ratings, but high valuations and competitive pressures pose risks. Continued execution on AI networking demand could drive further upside, while any slowdown in growth may trigger multiple compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
